[New - 7 Covid-19 Realities To Consider In 2023](https://wbbsec.com/opinions-and-features/)
[New - 7 Covid-19 Realities To Consider In 2023](https://wbbsec.com/opinions-and-features/)
powered by bulletin
In: Press Releases

PDF: 6.6.2014 Cytori Equity Financing

Cytori Closes $10MM in Registered Direct Financing

For Immediate Release

June 6, 2014

SAN DIEGO, CAWBB Securities acted as exclusive placement agent on a registered direct financing for Cytori Therapeutics, a clinical phase regenerative medicine company.  Cytori announced on May 30, 2014 that it had entered definitive agreements with accredited institutional investors.  Today Cytori announced the closing of the transaction.  The company raised an aggregate of $10 million before fees and expenses through the transaction. Cytori intends to use the proceeds for general corporate purposes, including the continued development, manufacture, marketing and sale of the Celution® System family of products, including related research and clinical trials, and other related research and development, sales and marketing, and general administrative expenses, working capital and capital expenditures.

About WBB Securities WBB Securities is a leading investment management, investment banking, and equity research firm.  Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities.  WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients.  The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche.  www.wbbsec.com

About Cytori Corporation Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® System product family. www.cytori.com